These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 22139432)
1. Management of type IIb dyslipidemia. Arai H; Ishibashi S; Bujo H; Hayashi T; Yokoyama S; Oikawa S; Kobayashi J; Shirai K; Ota T; Yamashita S; Gotoda T; Harada-Shiba M; Sone H; Eto M; Suzuki H; Yamada N; J Atheroscler Thromb; 2012; 19(2):105-14. PubMed ID: 22139432 [TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
3. Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events. Ina K; Hayashi T; Araki A; Kawashima S; Sone H; Watanabe H; Ohrui T; Yokote K; Takemoto M; Kubota K; Noda M; Noto H; Ding QF; Zhang J; Yu ZY; Yoon BK; Nomura H; Kuzuya M; Geriatr Gerontol Int; 2014 Oct; 14(4):806-10. PubMed ID: 24215618 [TBL] [Abstract][Full Text] [Related]
4. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
5. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study. Juonala M; Viikari JS; Rönnemaa T; Marniemi J; Jula A; Loo BM; Raitakari OT Arterioscler Thromb Vasc Biol; 2008 May; 28(5):1012-7. PubMed ID: 18309111 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902 [TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165 [TBL] [Abstract][Full Text] [Related]
9. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study. Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H; J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442 [TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia in the metabolic syndrome: clinical implications and management. Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Raal FJ Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742 [TBL] [Abstract][Full Text] [Related]
13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related]
17. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. Hermans MP; Valensi P Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):118-129. PubMed ID: 29493554 [TBL] [Abstract][Full Text] [Related]
18. Management of dyslipidemia in patients with metabolic syndrome. Cziraky MJ J Am Pharm Assoc (2003); 2004; 44(4):478-88; quiz 489-90. PubMed ID: 15372869 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952 [TBL] [Abstract][Full Text] [Related]
20. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Stahel P; Xiao C; Hegele RA; Lewis GF Can J Cardiol; 2018 May; 34(5):595-604. PubMed ID: 29459241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]